Jia-jun Wu
No. 110, Sect. 1, Jianguo N. Road, 402
Taitung, TNQ, Taiwan
Taitung, TNQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Stage shifts in national lung adenocarcinoma and the impact of opportunistic self-initiated LDCT screening in Taiwan: a nationwide population-based cohort study.
Journal: The Lancet regional health. Western Pacific
Published: January 29, 2026
Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma.
Journal: JTO clinical and research reports
Published: December 29, 2024
Taiwan Nationwide Study of First-Line ALK-TKI Therapy in ALK-Positive Lung Adenocarcinoma.
Journal: Targeted oncology
Published: September 18, 2024
Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib.
Journal: Therapeutic advances in medical oncology
Published: June 22, 2023
A combination of oxygenation and driving pressure can provide valuable information in predicting the risk of mortality in ARDS patients.
Journal: PloS one
Published: May 17, 2023
Thoracic radiotherapy may improve the outcome of extensive stage small cell lung carcinoma patients treated with first-line immunotherapy plus chemotherapy.
Journal: Anti-cancer drugs
Published: October 07, 2022
Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant).
Journal: Medicine
Published: October 12, 2021
Impact of tumor disappearance ratio on the prognosis of lung adenocarcinoma ≤2 cm in size: A retrospective cohort study.
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: March 10, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026